Since a single biopsy does not reflect expression heterogeneity within a single tumor, expression in metastatic lesions, or up- and downregulation of cancer markers during treatment, these techniques often fail at representing the overall status of HER2 expression [2,24]. The gene discussed is ERBB2; the disease is cancer.